Amyloidosis: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• TTR 56
• BCMA 11
• APOE 0
• SGLT2 0
• CD19 4
• MAPT 0
• CD38 0
• TNF 0
• APP 0
• BCL-2 0
• RET 0
• SNCA 0
• TREM2 0
• GPRC5D 2
• IL-1 0
• IL-6 0
• JAK 0
• LAG-3 0
• PPAR 0
• BACE1 0
• CFTR 0
• CXCR4 0
• EGFR 0
• HIF-1 0
• NRF2 0
• PARP 0
• PI3K 0
• TLR4 0
• TP53 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling the Role of Cerebral Amyloid-beta Angiopathy in Epilepsy: Inflammatory Pathways and Interneuron Dysfunction (EPICAA)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Germany· EU contribution €217,965· until Feb 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  The Mechanisms of neuronal silencing in Alzheimer’s Disease – investigation of cellular and network mechanisms in mouse models of β-amyloidosis (MONSil-AD)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €1,482,666· until Dec 2030

• European Commission (Horizon 2020) · ERC-COG

  A unified drug discovery platform for protein misfolding diseases (ProMiDis)

  Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk· Vari-Athens, Greece· EU contribution €1,972,000· until Feb 2027

4 of 4 running projects, newest first. Listed amounts together: €3.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 3
• Gene Expression Profiling 3
• Sequence Analysis, RNA 3
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 2
• Mass Spectrometry 14
• Flow Cytometry 1
• Immunohistochemistry 14
• Positron-Emission Tomography 33
• Magnetic Resonance Imaging 95
• Machine Learning 13
• Deep Learning 4
• Cohort Studies 42
• Genome-Wide Association Study 2

• Small Molecule Stabilization of Diverse Amyloidogenic Immunoglobulin Light Chains Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry.

  J Mol Biol, Jun 2026

• Proteomic profiling of whole tissue sections in cardiac ATTR amyloidosis reveals increased extracellular matrix remodeling.

  Cardiovasc Pathol, Jun 2026

• Amyloid in Primary Hip Arthroplasty Specimens: An Opportunity for Early Detection of Amyloidosis?

  J Arthroplasty, May 2026

• Current Standards and Perspectives in Proteomics for Cardiac Amyloidosis.

  Anal Chem, Mar 2026

• Tissue characterization in cardiac amyloidosis: a joint consensus document by the gruppo di studio di cardiopatologia (SIAPEC) and the SIC/ANMCO Italian cardiac amyloidosis network (RIAC).

  J Cardiovasc Med (Hagerstown), Jan 2026

• Multiplexed Isotope-Coded Mass Spectrometry Footprinting Enables Broad Heteroatom-Residue Mapping and Uncovers Noncanonical Ligand-Binding Sites in Amyloidosis Proteins.

  Anal Chem, Jan 2026

• Mini review on the laboratory diagnosis of amyloidosis: An overview of methods, applications, and trends in analytical approaches.

  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, Jan 2026

• Mass spectrometry footprinting reveals how kinetic stabilizers counteract transthyretin dynamics altered by pathogenic mutations.

  Proc Natl Acad Sci U S A, Dec 2025

• A Covalent Protein Painting Assay Differentiates Amyloid-β Polymorphs in Alzheimer Disease.

  J Proteome Res, Dec 2025

• Validation of a Mass Spectrometry-Based Proteomics Molecular Pathology Assay.

  Mol Cell Proteomics, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.